{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T23:20:33Z","timestamp":1777936833640,"version":"3.51.4"},"reference-count":16,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,7,13]],"date-time":"2022-07-13T00:00:00Z","timestamp":1657670400000},"content-version":"vor","delay-in-days":377,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American College of Cardiology"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1016\/j.jacc.2021.04.080","type":"journal-article","created":{"date-parts":[[2021,5,17]],"date-time":"2021-05-17T10:42:37Z","timestamp":1621248157000},"page":"153-155","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Do Mineralocorticoid Receptor Antagonists Suppress Atrial\u00a0Fibrillation\/Flutter?"],"prefix":"10.1016","volume":"78","author":[{"given":"Gerald V.","family":"Naccarelli","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edward J.","family":"Filippone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Foy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacc.2021.04.080_bib1","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2021.04.080_bib2","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1161\/CIRCULATIONAHA.120.051898","article-title":"Finerenone and cardiovascular outcomes in patients with chronic kidney disease and type 2 diabetes","volume":"143","author":"Filippatos","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2021.04.080_bib3","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.bcp.2019.07.001","article-title":"The non-steroidal mineralocorticoid receptor antagonist finerenone prevents cardiac fibrotic remodeling","volume":"168","author":"Lavall","year":"2019","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.jacc.2021.04.080_bib4","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.jacc.2021.04.079","article-title":"Finerenone reduces new-onset atrial fibrillation in patients with chronic kidney disease and type 2 diabetes","volume":"78","author":"Filippatos","year":"2021","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2021.04.080_bib5","doi-asserted-by":"crossref","first-page":"2859","DOI":"10.1681\/ASN.2018050514","article-title":"Cardiovascular events after new-onset atrial fibrillation in adults with CKD: results from the Chronic Renal Insufficiency Cohort (CRIC) study","volume":"29","author":"Bansal","year":"2018","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.jacc.2021.04.080_bib6","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1146\/annurev-physiol-021119-034650","article-title":"Regulation and effects of FGF23 in chronic kidney disease","volume":"82","author":"Musgrove","year":"2020","journal-title":"Ann Rev Phys"},{"key":"10.1016\/j.jacc.2021.04.080_bib7","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1161\/CIRCULATIONAHA.119.044183","article-title":"Effect of dapagliflozin on atrial fibrillation in patients with type 2 diabetes mellitus: insights from the DECLARE-TIMI 58 trial","volume":"141","author":"Zelniker","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2021.04.080_bib8","first-page":"254","article-title":"Dapagliflozin in HFrEF patients treated with mineralocorticoid receptor antagonists. An analysis of DAPA-HF","volume":"9","author":"Shen","year":"2021","journal-title":"J\u00a0Am Coll Cardiol HF"},{"key":"10.1016\/j.jacc.2021.04.080_bib9","doi-asserted-by":"crossref","first-page":"118","DOI":"10.15420\/aer.2018.18.2","article-title":"Risk factor management in atrial fibrillation","volume":"7","author":"Brandes","year":"2018","journal-title":"Arrhythm Electrophysiol Rev"},{"key":"10.1016\/j.jacc.2021.04.080_bib10","doi-asserted-by":"crossref","first-page":"5135","DOI":"10.1016\/j.ijcard.2013.08.022","article-title":"Impact of aldosterone antagonists on the substrate for atrial fibrillation: aldosterone promotes oxidative stress and atrial structural\/electrical remodeling","volume":"168","author":"Mayyas","year":"2013","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jacc.2021.04.080_bib11","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1056\/NEJMoa0805710","article-title":"Valsartan for prevention of recurrent atrial fibrillation","volume":"360","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2021.04.080_bib12","article-title":"Effects of mineralocorticoid receptor antagonists on atrial fibrillation occurrence: a systematic review, meta-analysis, and meta-regression to identify modifying factors","volume":"8","author":"Alexandre","year":"2019","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.jacc.2021.04.080_bib13","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1016\/j.jacc.2011.11.063","article-title":"Eplerenone and atrial fibrillation in mild systolic heart failure: results from the EMPHASIS-HF (Eplerenone in Mild Patients Hospitalization and SurvIval Study in Heart\u00a0Failure) study","volume":"59","author":"Swedberg","year":"2012","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2021.04.080_bib14","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s40256-019-00353-5","article-title":"Effect of spironolactone on atrial fibrillation in patients with heart failure with preserved ejection fraction: post-hoc analysis of the randomized, placebo-controlled TOPCAT trial","volume":"20","author":"Neefs","year":"2020","journal-title":"Am J Cardiovasc Drugs"},{"key":"10.1016\/j.jacc.2021.04.080_bib15","author":"Bayer"},{"key":"10.1016\/j.jacc.2021.04.080_bib16","doi-asserted-by":"crossref","first-page":"2987","DOI":"10.1093\/eurheartj\/ehx739","article-title":"Targeted therapy of underlying conditions improves sinus rhythm maintenance in patients with persistent atrial fibrillation: results of the RACE 3 trial","volume":"39","author":"Rienstra","year":"2018","journal-title":"Eur Heart J"}],"container-title":["Journal of the American College of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109721049676?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109721049676?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T13:43:26Z","timestamp":1760017406000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0735109721049676"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":16,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["S0735109721049676"],"URL":"https:\/\/doi.org\/10.1016\/j.jacc.2021.04.080","relation":{},"ISSN":["0735-1097"],"issn-type":[{"value":"0735-1097","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Do Mineralocorticoid Receptor Antagonists Suppress Atrial\u00a0Fibrillation\/Flutter?","name":"articletitle","label":"Article Title"},{"value":"Journal of the American College of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacc.2021.04.080","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.jacc.2021.04.079","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 by the American College of Cardiology Foundation. Published by Elsevier.","name":"copyright","label":"Copyright"}]}}